Investing

Today's Market Winners and Losers

Stocks are up Monday over earnings beating estimates and easing concern in Europe. The Dow Jones Industrial Average is up 0.58%, the Nasdaq is up 0.76% and the S&P 500 is up 0.52%. Today’s market winners include a biotechnology company reporting a successful stem-cell treatment and a retailer whose founder may take the company private.  Meanwhile, the only loser is still struggling from the fallout of last week’s trading glitch on the New York Stock Exchange.

Here are Monday’s market winners and loser(s).

Biggest Winners

Shares of Pluristem Therapeutics, Inc. (NASDAQ: PSTI) are up 18.43% to $3.92 on trading volume of 3.2 million shares. The biotech company reported Monday its placenta-derived stem-cell treatment assisted restoration of bone-marrow in a patient suffering from lymphoma. Before Monday, the 52-week high was $3.85.

Shares of Best Buy Co. Inc. (NYSE: BBY) are up 15.25% to $20.32 on trading volume of 23.2 million shares. Company founder Richard Schulze announced he would make a bid of $24 to $26 a share to take the company private. The 52-week high is $28.53.

Biggest Loser

Shares of Knight Capital Group, Inc. (NYSE: KCG) are down 23.46% to $3.10 on trading volume of 43.6 million shares. A group of investors purchased $400 million in prefered stock in the company to keep it afloat after the fallout from last week’s trading glitch on the New York Stock Exchange. The 52-week low is $2.27.

Samuel Weigley

Sponsored: Want to Retire Early? Here’s a Great First Step

Want retirement to come a few years earlier than you’d planned? Orare you ready to retire now, but want an extra set of eyes on your finances?

Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.

Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.